Overview

The DuoBody platform is a versatile platform technology for the discovery and development of bispecific antibodies that may improve antibody therapy of cancer, autoimmune, infectious and central nervous system disease. Bispecific antibodies (also known as dual-targeting molecules) bind to two different epitopes, either on the same or on different targets. This may improve the antibodies' specificity and efficacy in inactivating the disease target cells. DuoBody molecules are unique in combining the benefits of bispecificity with the strengths of conventional antibodies, which allows DuoBody molecules to be administered and dosed as other antibody therapeutics. Genmab's DuoBody platform generates bispecific antibodies via a fast and broadly applicable process that is easily performed at discovery scale as well as commercial manufacturing scale.

The DuoBody platform serves as the basis of many bispecific antibodies in Genmab's product pipeline as well as products of our partners and in 2021, the U.S. FDA approved the first therapy created using DuoBody technology platform. The DuoBody platform can be combined with Genmab's HexaBody platform (also known as Genmab's technology platform DuoHexaBody) as well as with other antibody engineering technologies.